Whitehawk Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
WHWK Nasdaq 2836 ir.whitehawktx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 - May 30th, 2026 12:30 pm
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference - May 28th, 2026 2:05 pm
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 - May 26th, 2026 4:26 pm
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise - May 21st, 2026 6:38 pm
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload - May 21st, 2026 3:05 pm
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit - May 20th, 2026 6:00 am
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy - May 16th, 2026 9:01 am
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - May 15th, 2026 6:00 am
May 2026's Promising Penny Stocks - May 14th, 2026 6:04 am
12 Health Care Stocks Moving In Wednesday's Intraday Session - May 13th, 2026 11:06 am
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - May 13th, 2026 6:06 am
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing - May 13th, 2026 6:00 am
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights - May 7th, 2026 6:00 am
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026 - Apr 19th, 2026 4:00 pm
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series - Apr 16th, 2026 2:05 pm
Discovering Whitehawk Therapeutics Among 3 Promising Penny Stocks - Apr 15th, 2026 6:05 am
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 - Apr 10th, 2026 5:00 am
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Mar 17th, 2026 2:30 pm
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - Mar 12th, 2026 6:00 am
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027 - Mar 10th, 2026 11:55 am